Sign in Subscribe
United States. Securities and Exchange Commission

Mallinckrodt plc Files Form 8-K Disclosure with SEC Amid Opioid Crisis Settlement Talks

Strategic Insights

— 2 min read

Mallinckrodt plc, a global biopharmaceutical company, has engaged in discussions with stakeholders, including parties holding substantial positions across its capital structure and representatives of the Opioid Master Disbursement Trust II. The company is actively evaluating its capital needs in light of its obligations under its opioid settlement and long-term debt, considering options such as transactions proposed by creditors and other stakeholders. The company's Board of Directors continues to analyze its situation and engage with various stakeholders, including representatives of the Trust. The outcome of this process is uncertain, and there is no assurance that the company will make a filing under the U.S. Bankruptcy Code or analogous foreign bankruptcy or insolvency laws.

Key Takeaways:

  • Mallinckrodt plc has filed a Form 8-K with the SEC on June 30, 2023, disclosing its ongoing discussions with stakeholders regarding its opioid crisis settlement.
  • The company is considering transactions proposed by creditors and other stakeholders to address its capital needs.
  • The Board of Directors is evaluating alternatives and related actions, including the potential initiation of bankruptcy proceedings.
  • The Opioid Master Disbursement Trust II is a key stakeholder in these discussions, having provided written notice to extend the due date of the Opioid Deferred Cash Payment from June 30, 2023, to July 7, 2023.
  • The company's substantial indebtedness and liquidity concerns are major factors in its current situation.
  • The company continues to engage with stakeholders, including representatives of the Trust, to address its capital needs and obligations.

Statistics:

  • The Opioid Deferred Cash Payment of $200 million was originally due on June 16, 2023, but was extended to July 7, 2023.
  • The company's indebtedness and liquidity concerns have led it to consider various options to address its capital needs.
  • The Opioid Master Disbursement Trust II has provided written notice to extend the due date of the Opioid Deferred Cash Payment twice, first to June 23, 2023, and then to June 30, 2023, and finally to July 7, 2023.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
  • Mallinckrodt plc's Form 10-K for the fiscal year ended December 30, 2022, available on the Company's website at http://www.mallinckrodt.com and http://www.sec.gov.
  • Mallinckrodt plc's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, available on the Company's website at http://www.mallinckrodt.com and http://www.sec.gov.

Read more